What Diliban Treats: Main Uses and Benefits

Diliban is a combination analgesic generally used to provide supportive symptomatic relief in adults whose pain has not been adequately controlled by alternative treatments. It is considered relevant for therapeutic areas that require a more robust, multimodal approach to managing pain, and contributes to improved day-to-day comfort.

Treating Moderate to Moderately Severe Pain

This medication is applied to ease persistent discomfort and symptoms related to physical discomfort associated with conditions like osteoarthritis, chronic, non-specific low back pain, and acute episodes following post-surgical or post-traumatic injury. The therapeutic focus is supportive relief for pain that has been inadequately controlled by other approaches. It is relevant for managing symptoms that interfere with daily functioning and is commonly used to help with symptoms that create noticeable functional strain.

This combination may assist with maintaining a sense of stability during difficult episodes, particularly when symptoms become more disruptive.

Eligibility Map: Who can and cannot use Diliban — official regulatory information

Eligibility scope

Populations for whom use is allowed (as stated in label): Adults and adolescents aged 12 years and over whose pain is considered to require a combination analgesic.

Populations for whom use is not recommended (if applicable): Patients with severe renal insufficiency, severe respiratory insufficiency, patients over 75 years (use requires greater caution), and breastfeeding women.

Populations for whom use is contraindicated: Children younger than 12 years; children under 18 years post-tonsillectomy/adenoidectomy; patients with severe hepatic impairment; acute intoxication with alcohol/opioids; MAOI use within 14 days; and known hypersensitivity.

Age-related eligibility rules: The minimum eligible age is 12 years. Use is absolutely contraindicated post-tonsillectomy/adenoidectomy in children under 18.

Condition-specific eligibility rules: Severe hepatic impairment is an absolute contraindication. Moderate hepatic or renal impairment restricts use and requires careful consideration.

Pregnancy and lactation eligibility status (if explicitly documented): Use should not be used during pregnancy due to the risk of Neonatal Opioid Withdrawal Syndrome. Breastfeeding is not recommended.

Eligibility-related restrictions: Use is permitted for patients with a history of seizures only if there are compelling circumstances.

Eligibility classifications (high-level)

Eligibility severity classification (as defined in official documents): Absolute Contraindication, Not Recommended, Restricted Use/Requires Caution.

Regulatory basis (EMA / FDA / etc.): Prescribing information from national regulatory authorities.

Eligibility-context constraints (as defined in official documents): Must not have conditions that increase seizure risk or acute respiratory compromise.

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents define eligibility by imposing absolute contraindications based on age, severe organ dysfunction, and acute intoxication. Further patient constraints are established through "not recommended" and "restricted use" categories, applying to conditions like pregnancy, severe renal impairment, and history of convulsive disorders. The profile strictly adheres to established population-based risk assessments.

Interactions with other medicines and products

Diliban (containing tramadol) has multiple documented interactions that may impact its safety and effectiveness. Monoamine oxidase inhibitors (MAOIs) are strictly contraindicated; Diliban must not be used concurrently or within 14 days of stopping MAOIs due to the heightened risk of Serotonin Syndrome, a potentially life-threatening condition.

Clinically Significant Combinations

Patients should avoid the use of Diliban with other tramadol-containing products and should not consume alcohol.

The mechanism of Diliban involves a multimodal strategy that targets non-overlapping pathways within the Central Nervous System (CNS) to suppress nociceptive signaling. The Tramadol component exerts its effect via two distinct actions: its active metabolite, M1, acts as an agonist at the mu-opioid receptor (MOR), which directly inhibits the transmission of nociceptive signals. Simultaneously, the parent drug weakly blocks the neuronal reuptake of Serotonin and Norepinephrine, amplifying the brain's own descending inhibitory pathways to dampen signaling. The Acetaminophen component complements this by reducing the activity of specific Cyclooxygenase (COX) enzymes in the CNS, decreasing the synthesis of the pain-sensitizing mediator, Prostaglandin E2 ( PGE2). Additionally, an Acetaminophen metabolite modulates spinal signaling via Cannabinoid (CB1) and TRPV1 receptors. This combined neurochemical modulation reduces the sensitization of central neurons and influences the threshold for nociceptive signaling.

Diliban is administered exclusively via the oral route as a fixed-dose combination tablet containing 37.5 mg of Tramadol and 325 mg of Acetaminophen. The standard starting dose for adults is two tablets taken as needed for persistent discomfort, with doses repeated every four to six hours.

Usage is governed by strict limitations on exposure. The minimum time between doses must be respected, and the maximum daily intake is eight tablets. This regimen is formally designated for short-term use, typically not exceeding five days. The medication can be taken independently of meal times (with or without food), and the tablets must be swallowed whole without being crushed or broken, which is a key administration principle.

High-level constraints restrict the co-administration of Diliban with any other product that contains either Tramadol or Acetaminophen to prevent exceeding maximum daily limits. Furthermore, established usage principles dictate that the lowest effective dosage must be used for the shortest possible duration.

For patients with severe renal impairment (CrCl < 30 mL/ min), the maximum dosing frequency is reduced to two tablets every 12 hours. Use is generally not permitted in cases of severe hepatic impairment. Upon discontinuation after long-term use, a gradual downward taper of the dose is required.

Diliban: Recent Clinical Evidence

Understanding the Research Basis for the Combination Analgesic

Diliban is a medicine studied as a fixed-dose combination (FDC) of two existing analgesics, Tramadol and Acetaminophen. Researchers primarily focused on exploring how the two active ingredients, when combined in a single tablet, may work differently than when each is taken alone. The research examined the combination's profile relative to its components to define the parameters of its use.

Studies in this area focused on the principles of pain relief, and findings describe patterns observed in comparing the combination product to the individual components given separately. This research helps contextualize how patients reported their experience of relief when receiving the dual-agent approach; research does not determine whether an individual will respond similarly.

Evidence for Use in Acute, Short-Term Pain

Research has been conducted to evaluate the FDC for short-term situations, such as pain following minor procedures or acute injury. These studies were primarily short-term Randomized Controlled Trials (RCTs) involving adult patients experiencing pain classified as moderate to moderately severe.

These studies monitored patient-reported outcomes describing perceived discomfort over defined, short time intervals. The research reports the changes observed in these pain scales and studies observed the outcomes related to phases of heightened symptom activity. Follow-up durations were typically limited to the acute event.

Evidence for Use in Persistent, Chronic Pain Conditions

In the context of chronic pain, the FDC was evaluated in studies that examined outcomes related to physical discomfort associated with conditions such as osteoarthritis and persistent low back pain. These trials included adult patients whose pain was not fully addressed by other medication and monitored symptoms over observation periods typically lasting up to three months.

Findings describe the patterns observed in the studies regarding the values recorded for pain scores and self-reported physical function measurements, which were compared to placebo. Results apply only to the populations studied during those trial periods, providing insight into short-term changes.

Duration of Studies and Long-Term Follow-up

Most high-certainty research for the FDC centered on short-term or intermediate efficacy, meaning follow-up durations were limited. For chronic pain, core clinical trials typically monitored patients for around three months.

This means that while research has explored how symptoms change during these defined time frames, there is limited information for long-term outcomes. The sustained, long-term effects are not fully established by the currently available data.

Research Gaps and Areas of Uncertainty

While the evidence base for the FDC's intended principle is established, some research questions remain. A key limitation is that there is limited information for long-term outcomes regarding sustained effects beyond the typical trial window. The consistency of the evidence varies across studies when assessing functional status measures (like daily activity levels) in some chronic pain conditions, and comparative evidence is lacking against all specific, alternative multimodal regimens. The findings help highlight what is known—and what is still uncertain—about this particular combination medicine.

Common questions about Diliban (FAQ)

Q: Does Diliban cause weight gain or loss?

Official safety information has documented weight loss as a possible adverse reaction to the medicine. However, this effect is not classified among the most frequently observed.

Q: Are there any foods or drinks that should be strictly avoided with Diliban?

Official regulatory documents describe the importance of avoiding alcohol while using Diliban. Additionally, some official sources advise caution or avoidance regarding grapefruit juice due to its potential to affect how the body processes the medicine.

Q: What is the difference between the generic and brand name Diliban?

Regulatory agencies specify that generic versions of a medicine must contain the same active ingredients and meet the same safety and effectiveness standards as the original brand-name product. While the therapeutic benefit is considered equivalent, generic products may contain different inactive ingredients and usually have a different appearance.

Q: Are there different strengths or versions of Diliban?

The most common form is an oral tablet containing 37.5 mg of Tramadol and 325 mg of Acetaminophen. Regulatory approvals in different regions indicate that this fixed-dose combination may be available in other strengths or forms, such as effervescent tablets.

Q: Can Diliban interact with common supplements like multivitamins or fish oil?

Official medical safety information does not specifically list interactions with common supplements like multivitamins or fish oil. However, as a general precaution, regulatory guidance describes the need for caution regarding herbal remedies and other supplements due to the potential for unforeseen interaction risks.

Q: Does Diliban affect blood pressure readings?

Official safety information includes reports of effects on the cardiovascular system. These reactions may include postural hypotension, which is a drop in blood pressure when changing position (such as standing up). Other less common effects reported are cardiovascular regulation anomalies.

Q: Why do some people say Diliban stopped working after a few months?

Official prescribing information states that the medicine is formally designated for short-term use. The risk of developing drug dependence is documented as increasing with prolonged use, which can be a factor affecting perceived effectiveness over extended periods.

Q: What are the rules for Diliban use in people with kidney problems?

Use is generally not recommended in cases of severe renal impairment (poor kidney function). For patients with a less severe reduction in kidney function, regulatory documents indicate that the medicine may require a dose reduction and increased time intervals between doses.

Q: What are the rules for Diliban use in people with liver disease?

The medicine is contraindicated (use is not permitted) in cases of severe hepatic impairment (severe liver disease). Furthermore, the official documents contain a serious warning regarding the potential for hepatotoxicity (liver damage) due to the acetaminophen component.

Q: Do I need a special diet when using Diliban?

According to official administration guidelines, the tablets can generally be taken with or without food. A specific or special restrictive diet is not a part of the standard usage instructions, beyond the avoidance of alcohol and certain juices.

Q: Why is Diliban sometimes described as a 'pro-drug'?

Regulatory documents describe how the Tramadol component is processed, or metabolized, by the body into an active substance known as M1. This active substance then acts in the nervous system and contributes significantly to the overall pain relief.

Q: Are there specific genetic factors that affect how Diliban works?

Official safety warnings note that genetic variations in a liver enzyme called CYP2D6 can influence how the body processes the Tramadol component. This genetic difference may impact the medicine's effectiveness and increase the risk of certain adverse effects.

Q: Is Diliban a prescription-only medicine?

Yes, Diliban is classified as a prescription-only medicine. Because it contains Tramadol, it is also federally scheduled as a Controlled Substance (Schedule IV) by regulatory authorities.

Q: What are the signs of an allergic reaction to Diliban?

Signs of an allergic reaction reported in official safety documents include skin rash, itching, hives, or swelling of the face, lips, tongue, or throat. The appearance of these signs is officially recognized as requiring prompt medical consultation.

Q: Does Diliban affect sleep patterns?

Official safety documents list somnolence (drowsiness) as a very common effect of the medicine. Other possible effects on sleep include reports of sleep disorders and insomnia.

How to Store and Dispose of Diliban

Storage and disposal instructions for Diliban (Tramadol/Acetaminophen) are officially mandated to ensure stability and safety, particularly due to the opioid component.

Official Storage Requirements

Diliban must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and must not be frozen. The tablets should remain in their original, tightly closed container and be protected from light, heat, and moisture. As a controlled substance, Diliban must be kept in a safe, secure place and out of the reach and sight of children; accidental ingestion can be fatal.

️ Disposal Instructions

The preferred method for discarding unused or expired tablets is via an authorized drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an unappealing substance, sealed in a bag, and disposed of in household trash in accordance with local requirements.